Philippe Chambon

“Having been on the executive leadership teams of three publicly held companies, I value Board participation, and Philippe, as a member of our Board, has played a critical role in our success.”

Bryan Birch, Chief Executive Officer, Truveris, Inc.

Philippe Chambon

Managing Director, New York, NY
Philippe Chambon, MD, PhD, is a Managing Director and founder of New Leaf Venture Partners.  He concentrates on Information Convergence and Biopharmaceutical investments.  He is currently on the board of Karos Pharmaceuticals, QPID Health, Treato, Ltd., Truveris, Inc. and VaxInnate Corporation.  His career in Venture Capital started in 1995 when he joined The Sprout Group. Prior to that, he served as Manager in the Healthcare Practice of The Boston consulting Group from 1993 to 1995.  From 1987 to 1993, he was an executive with Sandoz Pharmaceutical, where he led strategic product development, portfolio management and pre-marketing activities in his capacity as Executive Director of New Product Management.  Philippe did graduate research in molecular immunology at The Pasteur Institute and earned a M.D., Ph.D. from the University of Paris.  Philippe also has an M.B.A. from Columbia University in New York.


Board Seats and Investments

Notable Alumni Investments

Audax Health Solutions (Acquired by Optum/UnitedHealth)
Auxilium Pharmaceuticals (AUXL)
Charles River Labs
ePocrates (EPOC, Acquired by athenahealth)
Focus Diagnostics (Acquired by Quest Diagnostics)
Pharsight Corp. (NASDAQ: PHST, Acquired by Tripos)
Phase Forward (NASDAQ: PFWD, Acquired by Oracle)
Sapient Health Networks (Acquired by WebMD)
Spotfire (Acquired by Tibco)